Abiopharma

New Form NT 10-Q - PLUS THERAPEUTICS, INC. Filed: 2025-05-15 AccNo: 0000950170-25-072596 Size: 70 KB

New Form SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC Filed: 2025-05-15 AccNo: 0001104659-25-049410 Size: 7 KB

New Form NT 10-Q - Neuphoria Therapeutics Inc. Filed: 2025-05-15 AccNo: 0001213900-25-044176 Size: 21 KB

New Form SCHEDULE 13G - Relay Therapeutics, Inc. Filed: 2025-05-15 AccNo: 0001641172-25-010853 Size: 16 KB

New Form 8-K - Aditxt, Inc. Filed: 2025-05-15 AccNo: 0001213900-25-044174 Size: 660 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation …

New Form SCHEDULE 13G - Stereotaxis, Inc. Filed: 2025-05-15 AccNo: 0001641172-25-010864 Size: 8 KB

New Form NT 10-Q - NanoVibronix, Inc. Filed: 2025-05-15 AccNo: 0001641172-25-010863 Size: 31 KB

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

New Form SCHEDULE 13G/A - Lyell Immunopharma, Inc. Filed: 2025-05-15 AccNo: 0001104659-25-049403 Size: 22 KB

New Form 8-K - Doximity, Inc. Filed: 2025-05-15 AccNo: 0001516513-25-000044 Size: 568 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 144 - MERIT MEDICAL SYSTEMS INC Filed: 2025-05-15 AccNo: 0001950047-25-003044 Size: 4 KB

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results